NIA's #1 COVID-19 Treatment Play

NIA is excited to announce BetterLife Pharma (CSE: BETR) as its new #1 COVID-19 stock suggestion.

BETR has just announced that it has entered into an agreement to acquire worldwide rights (other than in Greater China, Japan and ASEAN countries) to commercialize and sell AntiCovir, a potential COVID-19 treatment, from Altum Pharmaceuticals Inc.

AntiCovir is being developed as a novel interferon alpha2b (IFNa2b) inhalation formulation. IFNa2b has been used to treat COVID-19 in China. Subject to receiving marketing authorization, AntiCovir may be used to treat patients early after COVID-19 infection which may prevent the progression to severe disease and need for hospitalization.

If successful in clinical trials, AntiCovir may potentially be positioned as an initial treatment for COVID-19 and similar viruses. AntiCovir has potential to be developed for use as prophylaxis against future Coronavirus and/or other serious respiratory virus pandemics. A 306 patient randomized, double-blind, placebo controlled Phase 3 trial for AntiCovir is projected to begin as early as July 2020 in Australia for the treatment of early COVID-19 infection.

Altum has already filed a U.S. provisional patent application related to AntiCovir which covers the composition and formulation of AntiCovir and the use of AntiCovir as a treatment for COVID-19.

Altum’s patent pending proprietary AntiCovir formulation improves stability of the IFNa2b and is adapted to inhalation delivery. All current IFNa2b are manufactured from recombinant clones that generate multiple IFNa2b isoforms, which are difficult to separate and are considered to be contaminants. AntiCovir is expected to be the first isoform free IFNa2b to come to market.

BETR also has a U.S. OTCQB symbol PVOTF.

BETR's wholly owned subsidiary for developing AntiCovir is called BLife Therapeutics and you can check out its web site by going to:

Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. NIA has been compensated by BETR USD$50,000 cash for a six-month marketing contract. This message is meant for informational and educational purposes only and does not provide investment advice.